Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.
carfilzomib
myelofibrosis
ruxolitinib
shRNA library screen
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
received:
30
08
2021
revised:
17
09
2021
accepted:
20
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
As the first FDA-approved tyrosine kinase inhibitor for treatment of patients with myelofibrosis (MF), ruxolitinib improves clinical symptoms but does not lead to eradication of the disease or significant reduction of the mutated allele burden. The resistance of MF clones against the suppressive action of ruxolitinib may be due to intrinsic or extrinsic mechanisms leading to activity of additional pro-survival genes or signalling pathways that function independently of JAK2/STAT5. To identify alternative therapeutic targets, we applied a pooled-shRNA library targeting ~5000 genes to a
Identifiants
pubmed: 34638347
pii: cancers13194863
doi: 10.3390/cancers13194863
pmc: PMC8507927
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Kay Kendall Leukaemia Fund
ID : KKL1072
Références
Hematol Oncol. 2018 Oct;36(4):701-708
pubmed: 30105794
Blood. 2015 Mar 12;125(11):1772-81
pubmed: 25573989
Clin Cancer Res. 2012 Jun 1;18(11):3008-14
pubmed: 22474318
Blood Rev. 2019 Mar;34:56-66
pubmed: 30501907
Cancers (Basel). 2021 Aug 21;13(16):
pubmed: 34439364
Medicine (Baltimore). 2018 Jun;97(23):e10920
pubmed: 29879032
Trends Cancer. 2020 Nov;6(11):960-973
pubmed: 32540455
Leukemia. 2012 May;26(5):1140-3
pubmed: 22094585
Nature. 2019 Jul;571(7765):355-360
pubmed: 31270458
Blood. 2014 Mar 20;123(12):1833-5
pubmed: 24443442
Cancer. 2000 Jan 15;88(2):344-51
pubmed: 10640966
Mol Cell Proteomics. 2011 May;10(5):R110.006924
pubmed: 21543789
PLoS One. 2015 Mar 17;10(3):e0114363
pubmed: 25781882
Am J Hematol. 2014 Sep;89(9):915-25
pubmed: 25124313
Blood. 2007 Jul 1;110(1):345-53
pubmed: 17374740
Blood Rev. 2006 Nov;20(6):333-42
pubmed: 16920238
Nature. 2013 Sep 19;501(7467):346-54
pubmed: 24048067
Br J Haematol. 2017 Jun;177(5):726-740
pubmed: 28340282
Nat Cell Biol. 2005 Aug;7(8):758-65
pubmed: 16056267
Acta Pharmacol Sin. 2016 Mar;37(3):354-67
pubmed: 26806299
BMJ. 2017 Oct 12;359:j4069
pubmed: 29025744
Br J Haematol. 2021 Jan;192(1):137-145
pubmed: 33022753
Front Immunol. 2018 Mar 05;9:422
pubmed: 29556237
Mol Oncol. 2015 Jan;9(1):309-22
pubmed: 25245324
Cancer Biol Ther. 2016 Jul 2;17(7):769-77
pubmed: 27246906
Cell Chem Biol. 2019 Mar 21;26(3):340-351.e3
pubmed: 30612952
Blood. 2009 Dec 3;114(24):5024-33
pubmed: 19828702
Br J Haematol. 2016 Jun;173(6):884-95
pubmed: 27071340
Haematologica. 2018 Jan;103(1):136-147
pubmed: 29122993
Blood. 2017 Aug 31;130(9):1125-1131
pubmed: 28674026
Clin Cancer Res. 2019 Apr 1;25(7):2323-2335
pubmed: 30563936
Leukemia. 2008 Aug;22(8):1636-8
pubmed: 18305559
Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16519-16528
pubmed: 31363046
Sci Rep. 2019 Jul 22;9(1):10558
pubmed: 31332222
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Cancer Sci. 2017 Mar;108(3):461-468
pubmed: 28092421
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Curr Hematol Malig Rep. 2015 Jun;10(2):96-103
pubmed: 25921386
Haematologica. 2013 Mar;98(3):404-8
pubmed: 22875628
Acta Haematol. 2017;137(2):106-112
pubmed: 28208145
Nature. 2020 Dec;588(7836):157-163
pubmed: 33239784
Clin Adv Hematol Oncol. 2019 Sep;17(9):500-505
pubmed: 31549971
J Hematol Oncol. 2017 Sep 29;10(1):156
pubmed: 28962635
Ann Hematol. 2020 Jul;99(7):1675-1676
pubmed: 32405693
J Biol Chem. 2014 May 2;289(18):12612-22
pubmed: 24627483
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
J Clin Oncol. 2015 Mar 1;33(7):732-9
pubmed: 25225420
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Am J Hematol. 2010 Aug;85(8):616-9
pubmed: 20540156
Int J Mol Sci. 2020 Apr 22;21(8):
pubmed: 32331228
Oncotarget. 2017 May 22;8(57):96710-96724
pubmed: 29228564
Cell Mol Life Sci. 2013 Dec;70(24):4681-94
pubmed: 23800989
Blood. 2007 Nov 1;110(9):3281-90
pubmed: 17591945
Blood Cancer J. 2019 Jan 25;9(2):12
pubmed: 30683837
Mol Cell Oncol. 2015 May 26;2(4):e1054552
pubmed: 27308511
Blood Adv. 2017 Feb 27;1(7):449-454
pubmed: 29296960
Biochem Pharmacol. 2000 Oct 15;60(8):1085-9
pubmed: 11007945
Biochem J. 2010 Dec 15;432(3):585-94
pubmed: 20919990
Anticancer Agents Med Chem. 2020;20(18):2316-2323
pubmed: 32067619
Leukemia. 2017 Sep;31(9):1962-1974
pubmed: 28008177
Science. 1998 Sep 11;281(5383):1680-3
pubmed: 9733516
N Engl J Med. 2015 Jan 8;372(2):142-52
pubmed: 25482145
FEBS Lett. 2003 Jul 10;546(2-3):228-32
pubmed: 12832045
Blood. 2010 Apr 15;115(15):3109-17
pubmed: 20130243
Lancet Oncol. 2016 Apr;17(4):e126
pubmed: 27300661
Blood. 2015 Sep 24;126(13):1551-4
pubmed: 26228487
Blood Cancer J. 2019 Sep 11;9(9):74
pubmed: 31511492
Front Oncol. 2019 Sep 24;9:939
pubmed: 31612105
Clin Cancer Res. 2011 Dec 1;17(23):7347-58
pubmed: 21976548